ID   VACO 10MS
AC   CVCL_5393
SY   VACO10MS; Vaco10MS; V10MS; VACO-10M; VACO10M; V10M; VACO 10; VACO10
DR   cancercelllines; CVCL_5393
DR   ColonAtlas; VACO10
DR   Cosmic; 948824
DR   Cosmic; 986022
DR   Cosmic; 1223152
DR   Cosmic; 1312319
DR   Cosmic; 2302023
DR   Cosmic; 2760086
DR   GEO; GSM784050
DR   GEO; GSM1346859
DR   GEO; GSM1374980
DR   IARC_TP53; 21745
DR   Progenetix; CVCL_5393
DR   Wikidata; Q54992654
RX   PubMed=6498841;
RX   PubMed=7761852;
RX   PubMed=8755562;
RX   PubMed=16418264;
RX   PubMed=20606684;
RX   PubMed=23272949;
RX   PubMed=24755471;
CC   Part of: AstraZeneca Colorectal cell line (AZCL) panel.
CC   Doubling time: 36 hours (PubMed=6498841).
CC   Microsatellite instability: Stable (MSS) (PubMed=24755471).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=16418264).
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: Metastatic; Omentum; UBERON=UBERON_0003688.
DI   NCIt; C5543; Cecum adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_5394 ! VACO 10P
SX   Female
AG   72Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 26
//
RX   PubMed=6498841;
RA   McBain J.A., Weese J.L., Meisner L.F., Wolberg W.H., Willson J.K.V.;
RT   "Establishment and characterization of human colorectal cancer cell
RT   lines.";
RL   Cancer Res. 44:5813-5821(1984).
//
RX   PubMed=7761852; DOI=10.1126/science.7761852;
RA   Markowitz S.D., Wang J., Myeroff L.L., Parsons R., Sun L.-Z.,
RA   Lutterbaugh J.D., Fan R.S., Zborowska E., Kinzler K.W., Vogelstein B.,
RA   Brattain M.G., Willson J.K.V.;
RT   "Inactivation of the type II TGF-beta receptor in colon cancer cells
RT   with microsatellite instability.";
RL   Science 268:1336-1338(1995).
//
RX   PubMed=8755562; DOI=10.1073/pnas.93.15.7832;
RA   Liu D.-C., Pearlman E., Diaconu E., Guo K., Mori H., Haqqi T.,
RA   Markowitz S.D., Willson J.K.V., Sy M.-S.;
RT   "Expression of hyaluronidase by tumor cells induces angiogenesis in
RT   vivo.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:7832-7837(1996).
//
RX   PubMed=16418264; DOI=10.1073/pnas.0510146103;
RA   Liu Y., Bodmer W.F.;
RT   "Analysis of P53 mutations and their expression in 56 colorectal
RT   cancer cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:976-981(2006).
//
RX   PubMed=20606684; DOI=10.1038/sj.bjc.6605780;
RA   Bracht K., Nicholls A.M., Liu Y., Bodmer W.F.;
RT   "5-fluorouracil response in a large panel of colorectal cancer cell
RT   lines is associated with mismatch repair deficiency.";
RL   Br. J. Cancer 103:340-346(2010).
//
RX   PubMed=23272949; DOI=10.1186/1755-8794-5-66;
RA   Schlicker A., Beran G., Chresta C.M., McWalter G., Pritchard A.,
RA   Weston S., Runswick S., Davenport S., Heathcote K., Castro D.A.,
RA   Orphanides G., French T., Wessels L.F.A.;
RT   "Subtypes of primary colorectal tumors correlate with response to
RT   targeted treatment in colorectal cell lines.";
RL   BMC Med. Genomics 5:66.1-66.15(2012).
//
RX   PubMed=24755471; DOI=10.1158/0008-5472.CAN-14-0013;
RA   Mouradov D., Sloggett C., Jorissen R.N., Love C.G., Li S.,
RA   Burgess A.W., Arango D., Strausberg R.L., Buchanan D., Wormald S.,
RA   O'Connor L., Wilding J.L., Bicknell D.C., Tomlinson I.P.M., Bodmer W.F.,
RA   Mariadason J.M., Sieber O.M.;
RT   "Colorectal cancer cell lines are representative models of the main
RT   molecular subtypes of primary cancer.";
RL   Cancer Res. 74:3238-3247(2014).
//